美国FDA定义的BCG无应答疾病的预后意义
本研究评估FDA定义的BCG无应答(诱导后至少1疗程维持BCG后复发)的预后价值,比较其与仅诱导后复发患者的肿瘤学结局。结果确认BCG无应答患者更需挽救性根治性膀胱切除术(54.5% vs 17.9%,p=0.002),选择二线保膀胱治疗者无复发率更低(23% vs 69.2%,p=0.003)。多因素分析显示BCG无应答独立预测更差的高级别无复发生存(HR 6.25,95%CI 2.27-16.67,p<0.001)和无膀胱切除生存(HR 3.85,95%CI 1.49-10.0,p=0.006)。
要点
- BCG无应答者根治性膀胱切除需求显著高于仅诱导后复发者(54.5% vs 17.9%)。
- BCG无应答者二线保膀胱治疗无复发率更低(23% vs 69.2%)。
- BCG无应答独立预测更差高级别无复发生存和无膀胱切除生存。
核心结论
- BCG无应答定义(诱导加至少1疗程维持BCG后高级别复发)具有预后价值,支持用于咨询和风险分层。
研究设计与样本
- 本研究比较BCG无应答患者(诱导加至少1疗程维持BCG后复发)与仅诱导BCG后复发患者的肿瘤学结局。
主要发现
- BCG无应答患者需挽救性根治性膀胱切除比例54.5%,仅诱导后复发者17.9%(p=0.002)。
- 选择二线保膀胱治疗者中,BCG无应答者无肿瘤复发率23%,仅诱导后复发者69.2%(p=0.003)。
- 多因素分析中BCG无应答独立预测更差高级别无复发生存(HR 6.25,95%CI 2.27-16.67,p<0.001)。
- BCG无应答独立预测更差无膀胱切除生存(HR 3.85,95%CI 1.49-10.0,p=0.006)。
关键数值与推荐
- BCG无应答定义为诱导后加至少1疗程维持BCG后高级别非肌层浸润性膀胱癌复发。
临床怎么用
- BCG无应答患者继续BCG获益可能性低,应考虑根治性膀胱切除或临床试验入组。
- BCG无应答定义可用于患者咨询和风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The category "BCG-unresponsive disease", formulated by experts at the request of the United States Food and Drug Administration, denotes a group of patients with recurrent non-muscle-invasive bladder cancer for whom continued BCG treatment is unlikely to provide benefit. Although quickly adopted for trial design, many of the nuances within the definition lack validation. In this study, we evaluated the prognostic value of BCG unresponsive designation (i.e. recurrence after induction plus at least 1 maintenance course of BCG) by comparing the oncologic outcomes of these patients with those recurring after induction BCG alone. We confirm that appropriately defined, BCG-unresponsive patients are more likely to require salvage radical cystectomy (54.5% vs 17.9%, p=0.002). Moreover, those opting for second-line bladder-sparing therapies are less likely to remain free of tumor recurrence (23% vs 69.2%, p=0.003). On multivariate analysis, BCG-unresponsive disease independently predicts inferior high-grade recurrence-free survival (hazard ratio [HR]: 6.25, 95% confidence interval [CI]: 2.27-16.67; p<0.001) and cystectomy-free survival (HR: 3.85, 95% CI: 1.49-10.0; p=0.006). Our data confirm the prognostic implication of the BCG unresponsive definition i.e. recurrence of high grade disease after induction and one course of maintenance BCG, and support its use in counseling and risk stratification of patients with tumor recurrence after BCG. Patient summary: Patients who have BCG-unresponsive disease, that is, high-grade non-muscle-invasive bladder cancer recurring after BCG induction and maintenance, have a low likelihood to respond to further BCG treatment and should consider radical cystectomy or clinical trial enrollment.
引用
- Li R, Tabayoyong WB, Guo CC, et al. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol. 2018. PMID: 30301695. doi:10.1016/j.eururo.2018.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。